Highlights Newsletter 4
This newsletter presents you the following key sessions:
1. Video interview with dr. Guy Young about rivaroxaban for pediatric venous thromboembolism (EINSTEIN-Jr study)
2. Significant reduction in severe graft-versus-host disease with post-transplantation cyclophosphamide after
allogeneic hematopoietic stem cell transplantation
3. Maintenance therapy with the hypomethylating agent CC-486 significantly prolongs the overall and relapse-free
survival of AML patients in remission after induction chemotherapy
4. Sustained progression-free and overall survival benefit of time-limited venetoclax-rituximab over bendamustine-
rituximab in relapsed/refractory CLL
5. The bispecific antibody mosunetuzumab exhibits promising activity in heavily pretreated non-Hodgkin lymphoma